Health Catalyst, Inc. (HCAT)

Health Catalyst’s filings show strong liquidity and a materially cleaner balance sheet after the Vitalware sale and credit-facility payoff, plus improving operating cash flow in 1H 2026. However, revenue trends are still negative in the most recent quarter and GAAP profitability has been poor due to repeated large goodwill impairments and ongoing operating losses. The setup is best viewed as a higher-risk turnaround/value situation where the key question is whether post-divestiture execution can stabilize growth and margins.

Dominant near-term signal is the announced leadership reset — Simeon Kohl named CEO and President with an inducement grant plus open-market share purchases, received mildly positively in-window — offset by analyst caution (Hold ratings, target cuts) and declining-revenue/billings coverage; sentiment delta is indeterminate at the numeric level (sparse baseline) with an item-level flat-to-slightly-positive read; legal screen clean, moderate red-flag cap applied (conflicting signals).

Mixed technical read. Constructive short-term tilt: price 1.79 holds above SMA20 1.69, EMA9 1.76, EMA21 1.75 and today's VWAP 1.78, with the MACD histogram positive and rising (+0.02) and RSI 52 neutral-to-firm; but the stock remains below SMA50 1.89 and SMA200 1.82 inside a longer post-earnings downtrend, ADX 12.8 shows no directional trend, and volume is far too thin. The chart is not the blocker — liquidity is: ~$782K/day (20-day average) and ~$593K/day (last 3 regular sessions) make any swing entry unfillable at fair prices and any protective stop unreliable, so the trade is Do Nothing despite the mildly constructive short-term structure.